Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENCEPT 10/11-21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is primarily metabolized by CYP3A4 via hydroxylation; etonogestrel is metabolized by CYP3A4 and CYP2C9.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 97-98% bound to albumin; desogestrel: 91-96% bound to SHBG and albumin
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2.7-3.9 L/kg; desogestrel: 1.5-2.0 L/kg; indicates extensive tissue distribution
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: ethinyl estradiol ~45% (first-pass metabolism), desogestrel ~76% (as active metabolite etonogestrel)
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic disease, hepatocellular carcinoma, or active liver disease. Use with caution in mild to moderate impairment; no specific dose recommendations available.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. Post-menarche, same dosing as adults: one tablet daily on days 1-21, then 7 placebo days.
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause. No specific dose adjustments in elderly due to lack of use.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use. This risk increases with age, especially in women over 35, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders and cardiovascular events,Liver disease,Hypertension,Gallbladder disease,Carbohydrate and lipid effects,Headache/migraine,Bleeding irregularities,Ectopic pregnancy,Depression,Hereditary angioedema,Chloasma,Ocular effects,Drug interactions
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Known or suspected breast cancer,Liver tumor or active liver disease,Uncontrolled hypertension,Diabetes with vascular involvement,Headache with focal neurological symptoms or migraine with aura age ≥35,Major surgery with prolonged immobilization,Renal disease,Adrenal insufficiency
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. However, grapefruit juice may increase ethinylestradiol levels; avoid excessive consumption (more than 1 liter per day). High-fat meals do not affect gestodene absorption. Maintain a consistent diet to avoid variability.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
GENCEPT 10/11-21 contains ethinylestradiol (EE) and levonorgestrel (LNG). EE/LNG is contraindicated during pregnancy. First trimester: Risk of congenital anomalies (e.g., heart defects, limb reduction) from exogenous sex hormones. Second/Third trimester: Increased risk of fetal harm, including genital abnormalities in female fetuses from androgenic effects of progestins. Use should be discontinued immediately if pregnancy occurs.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Small amounts of EE and LNG pass into breast milk. M/P ratio: EE ~0.4, LNG ~0.1. May reduce milk production, especially with high doses. Not recommended during breastfeeding; if used, lowest effective dose and monitor infant for jaundice or growth. Consider alternative contraception.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy, so no dosing adjustments apply. If inadvertent exposure, discontinue immediately.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
GENCEPT 10/11-21 is an oral contraceptive containing ethinylestradiol and gestodene. Administer daily at the same time to maintain consistent hormone levels. Breakthrough bleeding is common in first 3 cycles; if persistent, consider alternative formulations. Missed doses increase pregnancy risk; follow standard missed pill protocol. Caution in smokers >35 years due to thromboembolic risk. Monitor blood pressure at baseline and annually. This product is not indicated for emergency contraception.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, even during bleeding.,Missing a pill increases risk of pregnancy; refer to package insert for missed dose instructions.,Bleeding between periods may occur in early cycles; consult doctor if persistent.,Do not smoke while taking this medication, especially over age 35.,Inform doctor of all medications, including antibiotics and herbal supplements.,Seek immediate medical attention for signs of thrombosis: leg pain, chest pain, shortness of breath, or severe headache.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENCEPT 10/11-21 vs ALYACEN 777, answered by our medical review team.
GENCEPT 10/11-21 is a Oral Contraceptive that works by GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENCEPT 10/11-21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENCEPT 10/11-21 is: One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENCEPT 10/11-21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENCEPT 10/11-21 is classified as Category C. GENCEPT 10/11-21 contains ethinylestradiol (EE) and levonorgestrel (LNG). EE/LNG is contraindicated during pregnancy. First trimester: Risk of congenital anomalies (e.g., heart def. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.